Trikafta

(Elexacaftor)

Phase 3Small molecule

NNottingham University Hospitals NHS Trust

Trikafta is a small molecule that works as a CFTR Corrector.[2] It is being investigated across 1 indication, with its most advanced program in Phase 3.[1]

Trikafta is one of 42 small molecule programs targeting Cystic Fibrosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystic FibrosisActive, not recruiting

Cystic FibrosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

107 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Ibsrela

AArdelyx

Phase 3

1 2

Zyvox

Pfizer

Phase 2

2 3

Biaxin

AbbVie

Phase 2

2 4

Lamprene

Novartis

Phase 2

1 5

HSK31858

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

2 6

Sirturo

WWim Janssens

Phase 2

1 7

Tygacil

PPrism Pharmaceuticals

Phase 2

1 8

ELX/TEZ/IVA

Vertex Pharmaceuticals

Phase 3

18 9

Trikafta

NNottingham University Hospitals NHS Trust

Phase 3

4 10

VNZ/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Recruiting

Cystic Fibrosis

NCT07363304

Q3 2029

ApprovedActive, not recruiting

Cystic Fibrosis

NCT04602468

Q4 2030

Post-ApprovalRecruiting

ESS

NCT07148739

Clinical

Trials by Indication[1]

Cystic Fibrosis4 trials

Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior

Unknown status·NNottingham University Hospitals NHS Trust··NCT05699148·17 enrolled

Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.

Recruiting·MMeyer Children's Hospital IRCCS··NCT07363304·150 enrolled

Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)

Active, not recruiting·RRoyal College of Surgeons, Ireland·Approved·NCT04602468·206 enrolled

Show 1 more trial

iPS Cell Response to CFTR Modulators: Study of Trikafta in CF Patients Carrying Partial Function Mutations or N1303K CFTR

Completed·EEmory University·Phase 2·NCT03506061·42 enrolled

Treatment1 trial

Effect of One Year Elexacaftor-tezacaftor-ivacaftor Treatment

Completed·UUniversity Hospital, Strasbourg, France··NCT06331000·184 enrolled

Sinus Disease1 trial

Impact of Triple Combination CFTR Therapy on Sinus Disease.

Unknown status·JJennifer Taylor-Cousar··NCT04056702·31 enrolled

ESS1 trial

Ensuring Access to Optimal Therapy in CF: The ENACT Study

Recruiting·—·Phase 4·NCT07148739·95 enrolled

Unspecified1 trial

Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor

Unknown status·UUniversity of Erlangen-Nürnberg Medical School··NCT05576324·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Elexacaftor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Elexacaftor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Elexacaftor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nottingham University Hospitals NHS Trust company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: CFTR Corrector[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNottingham University Hospitals NHS Trust

Trikafta

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q3 2029

Q4 2030

Trials by Indication[1]

Cystic Fibrosis4 trials

Treatment1 trial

Sinus Disease1 trial

ESS1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News